External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience SMA Europe 2024
Roche and Genentech at

SMA Europe 2024

March 14 - March 16
Ghent, Belgium
sma-europe.eu
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 15 / Roche
Should all adults with SMA receive treatment?An experts’ debate
This symposium explored the benefits of, and barriers to, adults receiving treatment for SMA. In the form of a compelling debate, Prof. Laurent Servais and Prof. Blaž Koritnik discussed whether all adults living with SMA can and should receive disease-modifying therapy. Ms. Simona Joveska, a person living with SMA, moderated this debate and shared her personal experience and insights on navigating the condition as an adult.
Neuroscience Spinal Muscular Atrophy SMA-EUROPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 15 / Roche
Should all adults with SMA receive treatment? An experts’ debate
This symposium explored the benefits of, and barriers to, adults receiving treatment for SMA. In the form of a compelling debate, Prof. Laurent Servais and Prof. Blaž Koritnik discussed whether all adults living with SMA can and should receive disease-modifying therapy. Ms. Simona Joveska, a person living with SMA, moderated this debate and shared her personal experience and insights on navigating the condition as an adult.
Neuroscience Spinal Muscular Atrophy Real World Data - Real World Evidence SMA-EUROPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
Mar 14 / Roche and Genentech
Real-World Outcomes of Infants who Initiate Risdiplam▼ Under 2 Months of Age for the Treatment of Spinal Muscular Atrophy (SMA) in the US
This presentation describes the study design of a descriptive, non-interventional study that will characterize the real-world use of risdiplam▼ in infants with SMA in the US who initiated risdiplam▼ before 2 months of age following approval by the FDA of a label extension for risdiplam▼ in this population.
Neuroscience Spinal Muscular Atrophy SMA-EUROPE-2024
08:00 AM
Duration 90mins Ghent, Belgium
Correlation of individual SMN protein with observed efficacy in the risdiplam▼ clinical trials
Y Cleary, P Grimsey, CA Chiriboga, E Mercuri, T McIver, R Thomas, RS Scalco, H Kletzl
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Long-term comparative efficacy and safety of risdiplam▼ versus nusinersen in children with Type 1 SMA
CS Sutherland, N Hawkins, G Sajeev, R Evans, A Mahajan, DA Scott, J Nam, E Gaki, C, Kokaliaris
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
FIREFISH Parts 1 and 2: 48-month safety and efficacy of risdiplam▼ in Type 1 SMA
R Masson, M Mazurkiewicz-Beldzinska, G Baranello, O Boespflug-Tanguy, JW Day, N Deconinck, A Klein, E Mercuri, K Rose, L Servais, D Vlodavets, H Xiong, E Zanoteli, M El-Khairi, M Gerber, K Gorni, H Kletzl, L Palfreeman, A Dodman, BT Darras
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Exploration of the use of risdiplam▼ administration in patients with SMA who previously received gene therapy
CJ, Guittari, K, Gorni, M, Gerber, Y, Li
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
MANATEE: GYM329 (RO7204239) in combination with risdiplam▼ treatment with SMA
L Servais, BT Darras, J Morrow, F Muntoni,T Duong, M Rabbia, M Gerber, H Kletzl, E Gaki, S Fletcher, R Scalco, E Mercuri
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Bioequivalence and food effect assessment for a room-temperature stable risdiplam▼ tablet formulation in healthy volunteers
H Kletzl, K Heinig, B Jaber, W Y Yeung, H Coleman, B Lomeli, L Buckley, A Varghese
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Protocol for a Delphi consensus panel on assessing clinically meaningful treatment outcomes in adults living with SMA
K Sully, CA Chiriboga, T Duong, Y Erbas, J Glascock, N Gusset, R Muni-Lofra, C O’Connell, JF Vazquez-Costa, MC Walter, CJ Guittari, J Cochrane, LD Townson, J Kufakwaro, A Marciniak, D Riley, J Nam
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Post-hoc analysis of the SMA Independence Scale-Upper Limb Module (SMAIS-ULM) in individuals with Type 2 and non-ambulant Type 3 SMA using SUNFISH Part 2 data
K Sully, L Gao , C J Guittari, J Braid
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Assessing the feasibility of TREAT-NMD registries for characterizing adult patients with SMA receiving risdiplam▼ treatment
A Simpson, T Carmona, M Batech, SY Lee, N Bennett, S Edwards, CS Sutherland, C Marini-Bettolo, S Thiele, M Jagut, J Haberlová, V Hodgkinson, R Forbes, LB Murphy, V Matyushenko
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
A retrospective, non-interventional cohort study to compare adults with SMA receiving risdiplam ▼with untreated patients: Study design
A Simpson, M Batech, A Carmona, SY Lee, A Poll, S Edwards, CJ Guittari, CS Sutherland, C Marini-Bettolo, MC Walter, M Jagut, J Haberlová, V Hodgkinson, E Yiu, LB Murphy
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Ghent, Belgium
Real-World Outcomes of Infants who Initiate Risdiplam▼ Under 2 Months of Age for the Treatment of Spinal Muscular Atrophy (SMA) in the US
​​​Travis Dickendesher, Selina Tam, Dalia Moawad, S Edwards, Alex Simpson, Sheila Shapouri
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:30 PM
Duration 15mins Ghent, Belgium
RAINBOWFISH: Primary efficacy and safety data in risdiplam▼-treated infants with presymptomatic SMA
M A Farrar, R S Finkel, L Servais, D Vlodavets, E Zanoteli, M Al-Muhaizea, A Prufer, L Nelson,C Fischer, M Gerber, K Gorni, H Kletzl, L Palfreeman, E Gaki, P Fontoura, E Bertini
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 2mins Ghent, Belgium
Post-hoc analysis of the SMA Independence Scale-Upper Limb Module (SMAIS-ULM) in individuals with Type 2 and non-ambulant Type 3 SMA using SUNFISH Part 2 data
K Sully
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.